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In summary, based on our study, we still believe that con-
ventional Hemashield collagen impregnated Dacron patches,
used with carotid endarterectomy, likely carry higher periopera-
tive carotid thrombosis and stroke rates than PTFE or saphenous
vein patch. Further long-term studies are indicated if this patch is
to be used in the future. Perhaps the Finesse Hemashield patch
may prove to be a better alternative for those who prefer not to
use PTFE patches.
Ali F. AbuRahma, MD
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Regarding “Heparin modulates integrin function in
human platelets”
Sobel et al elegantly and convincingly show that unfraction-
ated heparin (UH) binds to the platelet integrin αIIbβ3 (Gp
IIb/IIIa).1 This binding then induced aggregation by outside-in
signaling. A few additional comments are of relevance.
The effect of UH on platelets is not uniform. UH is a more
powerful stimulator of in vitro and ex vivo aggregation in situa-
tions where platelet hyperactivity is present (eg, peripheral vascu-
lar disease,2 coronary artery disease,3,4 and anorexia nervosa2).
The stimulatory effect depends on which anticoagulant prepara-
tion is used. Low molecular weight heparin(oid)s (LMWH) are
less powerful stimulators than UH.5-8 Moreover, porcine mucosa
UH (used by Sobel et al) is a less powerful stimulator of aggre-
gation than bovine lung UH.5
The UH effect on aggregation is enhanced by fibrinogen
added in vitro.7 This finding may be relevant because UH
increases fibrinogen binding to platelets.1
UH also affects an early stage of platelet aggregation—the
shape change.8,10
Regarding “Prospective randomized study of carotid
endarterectomy with PTFE versus collagen
impregnated Dacron (Hemashield) patching:
Perioperative (30-day) results”
I read Dr James Edwards’ comments (J Vasc Surg
2002;35:176-7) on our paper, “Prospective randomized study of
carotid endarterectomy with PTFE versus collagen impregnated
Dacron (Hemashield) patching: Perioperative (30-day) results” (J
Vasc Surg 2002;35:125-30)1 with great interest, and I appreciate
the opportunity to respond.
Dr Edwards cited other reasons to explain the better out-
come of PTFE in regards to perioperative carotid thrombosis and
stroke, and the incidence of early (>50%) restenosis, other than
increased thrombogenecity of the Hemashield patch. We did not
conclude in our article that this was the only possible reason for
the thrombosis, and we have no explanation for these higher rates
of thrombosis and stroke. We simply raised the question as to
whether the Hemashield patch, impregnated with collagen, can
be thrombogenic in this location. This issue should be addressed
by future studies.
We would also like to point out to the readers that not all col-
lagen impregnated Dacron patches are the same as the conven-
tional Hemashield type that was used in our study. In the last few
years, a few authors, particularly surgeons in Europe, have
reported using the Finesse Hemashield with satisfactory results.2
The Finesse Hemashield has a different thickness from the con-
ventional Hemashield, which has been used in many medical cen-
ters in the USA over the last several years.
Dr Edwards also stated that the technical performance, pre-
operative antiplatelet/anticoagulation medication, patient selec-
tion, and statistical aberrancy might explain the results of the
superiority of PTFE versus Dacron. We agree that these are pos-
sibilities but don’t feel that technical performance was a factor in
this study because the two surgeons who contributed to this study
(AFA and JHK) have performed a few thousand carotid
endarterectomies over the last 20 years. The senior author (AFA)
has reported the results of carotid endarterectomy in two ran-
domized trials over the last several years using patch materials
other than Hemashield, such as saphenous vein, internal jugular
vein, or PTFE patching, with a perioperative stroke rate of
0.9%.3,4 The routine protocol used for this study was similar to
what has been used over the last 20 years and has been published
previously.3 However, it’s conceivable that a statistical error may
have been a factor in this study because of the sample size (200),
even though we exceeded the required sample size recommended
by our statistician.
Dr Edwards also indicated that the 5% acute carotid occlu-
sion rate was quite unusual. We agree with him, and as a matter
of fact, it was surprising to us. If you take the senior surgeon’s
(AFA) experience, the perioperative occlusion rate in this study
was 3 out of 90 (3.3%) in the Hemashield patch group, which is
relatively close to what has been reported by others (close to 2%,
as reported by Ricco et al2). Our perioperative carotid occlusion
rate in past endarterectomy trials has been <1%, which is similar
to that reported by Dr Edwards’ group, but different patches
were used in these (eg, saphenous vein or PTFE).
